SinuSys Corp. has hired Robert Hoxie as chief commercial officer. Hoxie will provide strategic sales and marketing direction for SinuSys and will be responsible for maintaining, developing and leading the company’s commercial operations.
“Robert has the perfect balance of medical device sales and marketing expertise, leadership experience in the ENT (ear, nose and throat) market, and a proven track record of commercial success,” said Thomas Schreck, president and CEO of Palo Alto, Calif.-based SinuSys. “We are excited to welcome him to the SinuSys executive team and look forward to his leadership in building a first class commercial organization to support the Vent-Os sinus dilation system, our unique osmotic dilation treatment for patients suffering from recurrent sinusitis.”
Hoxie has over 30 years of experience in medical device sales and marketing management. Most recently, he served as president and CEO of Gyrus ACMI’s ENT division where, according to a release from SinuSys, he transformed a minimal-growth company, heavily dependent on contract sales representatives, into a profitable organization within two years using direct sales, growing revenues to more than $50 million annually. Hoxie also was the member of the senior management team of several emerging companies, including Ovamed Corporation, Paramed Technologies, InnerDyne Corporation and Medical Innovations Corporation.
SinuSys makes the Vent-Os sinus dilation system and other osmotic and rate-controlled therapies for the treatment of sinusitis and other ear, nose and throat conditions. The company’s proprietary self-expanding, osmotic technology is designed to be less-traumatic, tissue-sparing and easier to use, company officials claim. The technology is designed to potentially enable clinicians to intervene at earlier stages of sinus disease.
The firm's market is the 20 percent of sinusitis patients whose disease is not resolved with drug therapy.